Application of initial anti-infectives and trends in children with septic shock

Objective: To investigate the pathogen composition, initial anti-infectives and pathogen coverage, and trends over the last 5 years in children with septic shock in pediatric intensive care unit (PICU). Methods: The single-center retrospective study included 257 children with septic shock who were a...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Zhonghua er ke za zhi = Chinese journal of pediatrics. - 1960. - 60(2022), 12 vom: 02. Dez., Seite 1288-1294
1. Verfasser: Liu, G (VerfasserIn)
Weitere Verfasser: Zheng, Y L C, Tan, N, Wang, L J, Liu, Y C, Gao, H M, Qian, S Y
Format: Online-Aufsatz
Sprache:Chinese
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Zhonghua er ke za zhi = Chinese journal of pediatrics
Schlagworte:English Abstract Journal Article Linezolid ISQ9I6J12J Vancomycin 6Q205EH1VU Anti-Infective Agents Anti-Bacterial Agents Carbapenems
LEADER 01000naa a22002652 4500
001 NLM349572879
003 DE-627
005 20231226042943.0
007 cr uuu---uuuuu
008 231226s2022 xx |||||o 00| ||chi c
024 7 |a 10.3760/cma.j.cn112140-20220511-00443  |2 doi 
028 5 2 |a pubmed24n1165.xml 
035 |a (DE-627)NLM349572879 
035 |a (NLM)36444432 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a chi 
100 1 |a Liu, G  |e verfasserin  |4 aut 
245 1 0 |a Application of initial anti-infectives and trends in children with septic shock 
264 1 |c 2022 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 30.11.2022 
500 |a Date Revised 30.11.2022 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Objective: To investigate the pathogen composition, initial anti-infectives and pathogen coverage, and trends over the last 5 years in children with septic shock in pediatric intensive care unit (PICU). Methods: The single-center retrospective study included 257 children with septic shock who were admitted to PICU of Beijing Children's Hospital, Capital Medical University from 2017 to 2021. The causitive pathogen composition, initial use of anti-infective drugs, pathogen coverage, and changes in recent years were analyzed. The children were divided into sufficient and insufficient coverage groups according to whether the pathogen were sufficiently covered by initial anti-infectives; community-and hospital-acquired groups; and with and without underlying disease groups. T test, rank-sum test and Chi-square test were used for comparison between the groups to investigate the differences in pathogen, treatment and prognosis. Results: A total of 257 septic shock children were included, with 162 males and 95 females, aged 36 (12, 117) months. The pathogen positive rate was 64.6% (166/257) and the in-hospital mortality was 27.6% (71/257). In the 208 pathogen-positive samples, bacteria was the most common (57.7%, 120/208) with G-negative bacteria predominating (55.8%, 67/120), followed by viruses (26.0%, 54/208). Nearly 99.2% (255/257) of the children were treated with antibacterial at the beginning, of whom 47.1% (121/257) were treated with carbapenems combined with vancomycin or linezolid. The proportion of 3 or more antibacterial combinations was higher in children with underlying diseases and hospital-acquired septic shock than in those without underlying disease or community-acquired septic shock (27.4% (49/179) vs. 14.1% (11/78), 29.4% (52/177) vs. 10.0% (8/80), χ2=5.35,11.56,all P<0.05). The proportion of initial combination of carbapenem and vancomycin or linezolid reduced from 52.5% (21/40) to 41.3% (19/46), and of adequate pathogen coverage increased from 40.0% (16/40) to 58.7% (27/46) in the last five years. Conclusions: The initial use of antibacterial drugs is common in children with septic shock in PICU, especially in those with hospital-acquired septic shock and underlying diseases. In recent years, antimicrobial combinations have decreased, but the pathogen coverage has improved, indicating that drug selection is more reasonable and accurate 
650 4 |a English Abstract 
650 4 |a Journal Article 
650 7 |a Linezolid  |2 NLM 
650 7 |a ISQ9I6J12J  |2 NLM 
650 7 |a Vancomycin  |2 NLM 
650 7 |a 6Q205EH1VU  |2 NLM 
650 7 |a Anti-Infective Agents  |2 NLM 
650 7 |a Anti-Bacterial Agents  |2 NLM 
650 7 |a Carbapenems  |2 NLM 
700 1 |a Zheng, Y L C  |e verfasserin  |4 aut 
700 1 |a Tan, N  |e verfasserin  |4 aut 
700 1 |a Wang, L J  |e verfasserin  |4 aut 
700 1 |a Liu, Y C  |e verfasserin  |4 aut 
700 1 |a Gao, H M  |e verfasserin  |4 aut 
700 1 |a Qian, S Y  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Zhonghua er ke za zhi = Chinese journal of pediatrics  |d 1960  |g 60(2022), 12 vom: 02. Dez., Seite 1288-1294  |w (DE-627)NLM136249191  |x 0578-1310  |7 nnns 
773 1 8 |g volume:60  |g year:2022  |g number:12  |g day:02  |g month:12  |g pages:1288-1294 
856 4 0 |u http://dx.doi.org/10.3760/cma.j.cn112140-20220511-00443  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_50 
912 |a GBV_ILN_61 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_130 
912 |a GBV_ILN_227 
912 |a GBV_ILN_244 
912 |a GBV_ILN_285 
912 |a GBV_ILN_294 
912 |a GBV_ILN_350 
912 |a GBV_ILN_665 
912 |a GBV_ILN_813 
951 |a AR 
952 |d 60  |j 2022  |e 12  |b 02  |c 12  |h 1288-1294